Vlad Coric, Biohaven CEO
In two separate moves, Biohaven seeks to repurpose failed Bristol Myers/Roche Duchenne drug while buying out small biotech
As Biohaven reported its fourth quarter and full-year 2021 earnings to investors, the biotech unveiled two new deals — a licensing deal with a Big Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
